Introduction {#sec1-1}
============

*Chryseobacterium indologenes* is a nonfermenting Gram-negative bacillus which is ubiquitously found in the environment. Recently, an upsurge of *C. indologenes* nosocomial infections has been reported because of the advances in newer diagnostic modalities, which have made identification of rare nonfermenters easier.\[[@ref1]\] We describe a case of *C. indologenes*-associated pleural effusion in a patient with aortic dissection.

Case Report {#sec1-2}
===========

A 42-year-old male patient presented to the emergency department with complaints of acute onset of severe chest pain and shortness of breath. There was no trauma or injury to the chest. The patient had no underlying history of diabetes, immunosuppression, or any other comorbid condition apart from a past history of aortic regurgitation. There was no recent history of hospitalization, indwelling catheters, or invasive procedures. On initial examination, the patient was conscious and well oriented with heart rate of 124/min, blood pressure of 190/71 mmHg, respiratory rate of 24/min, and 72% SpO~2~. Respiratory examination revealed bilateral vesicular breath sounds. All other organ systems were normal on examination. The hematological investigations were normal. Computed tomography aortic angiography revealed Type A aortic dissection with intimal flap extending from the aortic root proximally up to the left common iliac artery distally, and a large entry tear was present in the ascending aorta. The patient underwent a modified Bentall procedure with hemiarch repair and Alfieri mechanical valve (MV) repair for Type A aortic dissection. An initial regimen of meropenem, ofloxacin, and metronidazole was started.

The patient was readmitted after 2 weeks of surgery with high-grade fever (102°F). Laboratory tests revealed leukocytosis (15,000/mm^3^) and raised erythrocyte sedimentation rate (40 mm at the end of first hour (AEFH)). Blood cultures were sterile. A normally functioning MV was seen on echocardiogram. The patient was started empirically on meropenem and ceftriaxone for possible culture-negative endovascular infection. Within 24 h, the patient developed respiratory difficulty, and ultrasound chest revealed a massive right-sided pleural effusion with underlying consolidated lung. An intercostal drainage was performed, and pleural fluid was sent for bacterial culture.

Culture of the pleural fluid yielded convex, circular, and yellow-colored colonies on 5% sheep blood agar. Gram stain showed Gram-negative bacilli, which were nonmotile, catalase positive, oxidase positive, indole positive, and glucose nonfermenting. The isolate was further confirmed as *C. indologenes* by MALDI-TOF MS system (VITEK MS™; bioMerieux, France) with 99.9% confidence value of identification. Samples from the patient\'s surroundings including swabs from the dressing trolley, bed railing, mattress, in-use antiseptic solutions, and intravenous fluids were tested to determine the source of infection. However, all samples were negative for *C. indologenes*.

Despite antimicrobial therapy, leukocytosis and fever persisted. Susceptibility testing was performed using VITEK I automated system (BioMerieux Vitek, Inc.), and the isolate was susceptible to cotrimoxazole, minocycline, and tigecycline and resistant to aminoglycosides, fluoroquinolones, piperacillin/tazobactam, cefoperazone-sulbactam, third-generation cephalosporins, and carbapenems. Treatment was modified, and tigecycline and cotrimoxazole were started and continued for 10 days. The patient improved, and follow-up cultures of the pleural fluid were sterile. The patient was discharged at the end of the treatment period.

Discussion {#sec1-3}
==========

Majority of the infections caused by *C. indologenes* have been associated with certain predisposing conditions such as immunodeficiency, malignancies, presence of indwelling catheters, and invasive devices.\[[@ref2][@ref3]\] Our patient was immunocompetent. Surgical intervention could be the predisposing factor for acquisition of this infection. Isolation of this organism from a sterile site, absence of other pathogens, and response to treatment suggest that *C. indologenes* was responsible for pleural effusion in this case. Environmental screening failed to detect the source of infection. Although the biological sequence of events is unknown, the organism was possibly inoculated through a breach in the skin at the time of the surgery, possibly giving rise to a transient bacteremia and seeding into the pleural cavity.

*C. indologenes* presents with a high rate of resistance against commonly used antibiotics such as aminoglycosides, chloramphenicol, penicillins, aztreonam, cephalosporins, and carbapenems. Since the *C. indologenes* isolate was multidrug resistant, our patient did not respond to the empirical antibiotic therapy. The most often found active agents are newer fluoroquinolones, minocycline, cefepime, and cotrimoxazole.\[[@ref3][@ref4][@ref5]\] Our patient responded well to a combination of tigecycline and cotrimoxazole.

We searched the PubMed database for infections of the respiratory system caused by *C. indologenes* in adults and found 12 case reports [Table 1](#T1){ref-type="table"} and four studies.\[[@ref5][@ref18][@ref19][@ref20]\] To the best of our knowledge, this is the first report of pleural effusion due to *C. indologenes* in an immunocompetent individual with preexisting heart disease. This case further expands the clinical spectrum of this opportunistic pathogen. The choice of empirical therapy in such conditions also becomes important since most of these pathogens are multidrug resistant.

###### 

Respiratory system infections caused by *Chryseobacterium indologenes* in adult patients

  Years   Country   Age/sex     Possible predisposing condition                                      Sample                   Outcome              References
  ------- --------- ----------- -------------------------------------------------------------------- ------------------------ -------------------- ----------------------------------------------------------------
  2018    India     68/female   Connective tissue disorder, interstitial lung disease                ET aspirate              Expired              Agarwal *et al*., Indian J Crit Care Med 2018\[[@ref6]\]
  2017    Turkey    69/male     COPD                                                                 Sputum                   Improved             Soydan *et al*., Drug Discov Ther 2017\[[@ref7]\]
  2017    Japan     64/female   Adult T-cell leukemia/lymphoma                                       Sputum                   Expired              Imataki and Uemura Clin Case Rep 2017\[[@ref8]\]
  2016    Spain     NA          NA                                                                   NA                       NA                   Chiscano-Camón *et al*., Med Clin (Barc) 2016\[[@ref9]\]
  2016    Spain     63/female   Parietal oligodendroglioma postsurgery, chemotherapy, radiotherapy   BAL                      Improved             Peñasco *et al*., Med Intensiva 2016\[[@ref10]\]
  2015    Turkey    82/male     NA                                                                   Transtracheal aspirate   Improved             Nemli *et al*., Case Rep Infect Dis 2015\[[@ref11]\]
  2015    Tunisia   NA          NA                                                                   NA                       NA                   Ben Salah *et al*., Rev Pneumol Clin 2015\[[@ref12]\]
  2014    India     42/male     Gastric non-Hodgkin's lymphoma                                       Sputum                   Improved initially   Shahul *et al*., BMJ Case Rep 2014\[[@ref13]\]
  2013    USA       66/male     Trauma                                                               BAL                      Improved             Monteen *et al*., Ann Pharmacother 2013\[[@ref14]\]
  2013    USA       32/female   Metastatic breast cancer                                             Tracheal aspirates       Expired              Yasmin *et al*., J Med Case Rep 2013\[[@ref15]\]
  2010    Brasil    30/male     Idiopathic medullary aplasia, febrile neutropenia                    Tracheal aspirate        NA                   Ferreira Rde *et al*., Rev Bras Ter Intensiva 2010\[[@ref16]\]
  2007    France    NA          NA                                                                   NA                       NA                   Reynaud *et al*., Med Mal Infect 2007\[[@ref17]\]

COPD=Chronic obstructive pulmonary disease, BAL=Bronchoalveolar lavage, ET aspirate=Endotracheal aspirate, NA=Data not available

Conclusion {#sec1-4}
==========

Our report suggests that the pathogenicity and clinical significance of *C. indologenes* should not be underestimated. Prompt, appropriate-targeted antimicrobial therapy ensures a favorable outcome. Identification of the source of infection should be attempted wherever possible, as this will have implications for infection control.
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